Drugs / SHR-2173
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07390747 | Mar → May 2026 overdue | — | Atridia Pty Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07206758 | Nov 2025 → Jun 2026 overdue | autoimmune thrombocytopenia | Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06955598 | Nov 2024 → Nov 2025 | systemic lupus erythematosus | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06995001 | Apr → Nov 2024 | — | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07622342 | Jun 2026 → Sep 2027 expected | generalized myasthenia gravis | Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07299422 | Apr 2026 → Mar 2028 expected | systemic lupus erythematosus | Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07354932 | Mar 2026 → Apr 2027 expected | IgA glomerulonephritis | Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07289763 | Dec 2025 → Aug 2027 expected | idiopathic membranous glomerulonephritis | Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07229742 | Nov 2025 → Jun 2027 expected | lupus nephritis | Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-2173 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07390747 ↗ |
| Route | Subcutaneous | “multiple subcutaneous injections” NCT06955598 ↗ |